Literature DB >> 28259733

NFKBIZ in Psoriasis: Assessing the association with gene polymorphisms and report of a new transcript variant.

Pablo Coto-Segura1, Leire Gonzalez-Lara2, Juan Gómez3, Noemí Eiris2, Ana Batalla2, Celia Gómez2, Sheila Requena2, Rubén Queiro4, Belén Alonso3, Sara Iglesias3, Eliecer Coto5.   

Abstract

The IκBζ protein (NFKBIZ gene) is a nuclear inhibitor of NF-κB and plays an important role in the pathogenesis of Psoriasis (Psor). We sought to determine whether common NFKBIZ variants were associated with the risk of developing Psor. A total of 392 patients and 336 controls were genotyped for a common intron 10 indel that could affect pre-mRNA splicing. We found a significantly higher frequency of the insertion among the cw6-positive patients (p=0.01). Cw6-positive+intron 10 ins/ins were significantly more frequent in the patients (OR=3.61). The analysis of the cDNA from leukocytes showed a NFKBIZ transcript lacking exon 10, present in all the tested samples. This new alternative transcript lacks a domain predicted to interact with the NFKB1/p50 protein. Functional studies to define the effect of this alternative transcript on the regulation of the NF-κB pathway are necessary.
Copyright © 2017 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gene polymorphism; NF-KB; NFKBIZ; Psoriasis

Mesh:

Substances:

Year:  2017        PMID: 28259733     DOI: 10.1016/j.humimm.2017.02.008

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  5 in total

1.  NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis.

Authors:  Pablo Coto-Segura; Leire González-Lara; Ana Batalla; Noemí Eiris; Rubén Queiro; Eliecer Coto
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

2.  Genetic variants in the NF-κB signaling pathway (NFKB1, NFKBIA, NFKBIZ) and risk of critical outcome among COVID-19 patients.

Authors:  Daniel G Camblor; Daniel Miranda; Guillermo M Albaiceta; Laura Amado-Rodríguez; Elías Cuesta-Llavona; Daniel Vázquez-Coto; Julia Gómez de Oña; Claudia García-Lago; Juan Gómez; Eliecer Coto
Journal:  Hum Immunol       Date:  2022-06-21       Impact factor: 2.211

3.  Gene Variant in the NF-κB Pathway Inhibitor NFKBIA Distinguishes Patients with Psoriatic Arthritis within the Spectrum of Psoriatic Disease.

Authors:  Pablo Coto-Segura; Eliecer Coto; Leire González-Lara; Belén Alonso; Juan Gómez; Elías Cuesta-Llavona; Rubén Queiro
Journal:  Biomed Res Int       Date:  2019-11-11       Impact factor: 3.411

Review 4.  Genetic Variants of the NF-κB Pathway: Unraveling the Genetic Architecture of Psoriatic Disease.

Authors:  Rubén Queiro; Pablo Coto; Leire González-Lara; Eliecer Coto
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

Review 5.  Emerging role of IκBζ in inflammation: Emphasis on psoriasis.

Authors:  Preeti Gautam; Sylvain Maenner; Frédéric Cailotto; Pascal Reboul; Stéphane Labialle; Jean-Yves Jouzeau; Frédéric Bourgaud; David Moulin
Journal:  Clin Transl Med       Date:  2022-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.